Tag results:

liver fibrosis

The Anti-Fibrotic Drug Pirfenidone Inhibits Liver Fibrosis by Targeting the Small Oxidoreductase Glutaredoxin-1

[Science Advances] The authors showed that pirfenidone, an anti-lung fibrosis drug, inhibited hepatic stellate cell activation and liver fibrosis in a Glutaredoxin-1 (GLRX)-dependent manner. Glrx depletion exacerbated liver fibrosis, and decreased GLRX and increased protein S-glutathionylation were observed in fibrotic mouse and human livers.

Advances of Natural Activators for Nrf2 Signaling Pathway on Cholestatic Liver Injury Protection: A Review

[European Journal of Pharmacology] Scientists review the effect of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway on alleviating cholestasis, and summarize recent evidence about natural Nrf2 activators with hepatoprotective effect in various models of cholestatic liver injury, thus providing theoretical reference for the development of anti-cholestatic drug.

Pantoprazole Ameliorates Liver Fibrosis and Suppresses Hepatic Stellate Cell Activation in Bile Duct Ligation Rats by Promoting YAP Degradation

[Acta Pharmacologica Sinica] Researchers investigated the effects of pantoprazole (PPZ), a proton pump inhibitor, against liver fibrosis in a bile duct ligation rat model, human hepatic stellate cell (HSC) line LX-2 and mouse primary HSCs, and explored the potential mechanisms underlying the effects of PPZ in vitro and in vivo.

Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease

[Clinical therapeutics] The authors summarize the emerging and more established therapeutic options considering the complex pathophysiology of nonalcoholic fatty liver disease and the important long-term sequelae of this condition.

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

[Genevant Sciences] Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.

Intercellular Crosstalk of Liver Sinusoidal Endothelial Cells in Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma

[Digestive and Liver Disease] Scientists summarize the current knowledge of how different crosstalk between liver sinusoidal endothelial cells and other liver cells, including hepatocytes, hepatic stellate cells, macrophoges, immune cells in liver and extra cellular matrix contribute to the physiological function and the progrssion from liver fibrosis to cirrhosis, or even to hepatocellular carcinoma.

Popular